All times are shown in CEST
8:50 am Chair’s Opening Remarks
9:00 am Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression
Synopsis
- Nouscom Cancer vaccines targeting neoantigens:
- Rely on effective neoantigens prediction methods
- Can encode a large number of neoantigens
- Induce a robust neoantigens’ specific CD4 and CD8 T cell immunity
- Cure large established tumours in mice when combined with checkpoint blockade
9:30 am Panel Discussion: Evaluating Combination Therapies
Synopsis
- The hasty evolvement of combination strategies
- Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumor immune activity
- Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting
- Discuss regulatory pathway and limitations to approve two new drugs
- How to identify a clear biologic effect caused by combination
- Improving Clinical Efficacy through Immunotherapy Combinations
10:00 am Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)
Synopsis
- Differences and synergies between personalized/shared neoantigen identification, and target prediction for infectious diseases
- Exploration of different IO epitope prediction tools and their extrapolation capabilities for general infectious diseases
- Use case: designing an optimal construct for intranasal RNA-based SARS-CoV2 vaccine
10:30 am Targeting antigens to antigen presenting cells induce effective anti-tumor efficacy as monotherapy and as combination therapy
Synopsis
- Vaccibody’s 3 modular format optimized for induction of rapid, strong and broad immune responses
- Tailoring the immune response profile by targeting different receptors on antigen presenting cells
- Combinations and applicability within personalized and off-the shelf cancer vaccines and beyond
11:00 am Morning Refreshments & Networking
PREDICTION & IDENTIFICATION
Examining Binding Affinity of Neo-epitopes to Determine Cancer Vaccination Strategies
11:30 am High-affinity Neoepitope-Specific T Cells Accumulate in Tumours
12:00 pm Characterizing Epitopes for Cancer Vaccines and T Cell Therapeutics
Identifying Novel Targets to Drive Development of Next Generation Cancer Vaccines
12:30 pm Are Immunogenic Tumours the Best Targets of Tumour Vaccination?
Synopsis
- Identifying the best targets for tumour vaccination
- Tumour infiltration and PDL1expression to identify the tumours that are more sensitive to vaccines
- Assessing non immunogenic tumours
- Outlining considerations for the future of neoantigens
CLINICAL TRANSLATION & MANUFACTURING
Addressing the Importance of Clinical Trial Design and Optimizing Lead Time to Accelerate Development of Neoantigen Therapies
11:30 am Designing the Right Clinical Trial for a Neoantigen Platform
Synopsis
- Evaluation of options for clinical trial design
- How to define better clinical endpoints
- Considerations for in-house development and manufacturing vs outsourcing
12:00 pm Entering clinical trials with a personalized oral bacteria-based DNA vaccine – Overcoming hurdles and challenges
Synopsis
- Selecting the neoantigen prediction technology
- Optimizing the manufacturing process to minimize the time to administration
- Ensuring compliance with regulatory requirements
- Designing the clinical study
Overcoming the Technical Challenges of Personalised Therapy to Allow For Seamless Therapeutic Delivery
12:30 pm Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy
Synopsis
- Considerations for process design and specifications for a personalized neoantigen based vaccine and a personalized neoantigen based cell therapy.
- Approaches for dealing with human to human variability as well as process variability.
- Key supply chain considerations for ensuring supply of personalized product to the early phase clinical trials
13:00 pm Lunch
2:00 pm TG4050 : Viral immunotherapy meets AI technology
Synopsis
- TG4050 is based on a decade long expertise in designing viral vectors
- Viral immunotherapy constitutes a promising modality harnessing the natural sensitivity of immune system to virus to target cancer cells
- Viruses can be modified to alter their immunogenic properties and enhance anti-tumor activity
- A review of how different viruses can be combined to enhance immunogenicity and optimize lead time
2:30 pm The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre- Clinical Results
Synopsis
- ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens
- Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity
- Be careful, common neoantigens may differ from common mutations
- The GEN-009 immunotherapy, designed with personalized ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009 101 Phase 1/2a clinical trial
3:00 pm Multi-step Screening of Neoantigens’ HLA- and TCR-interfaces Improves Prediction of Survival in Urothelial Bladder Cancer
3:30 pm Journey to CAR T-cell Therapy
Synopsis
• Emily Whitehead’s journey to become the first pediatric cancer patient to receive CAR T-cell therapy
• Establishing the Emily Whitehead Foundation to raise research funding and help more kids like Emily receive
less toxic therapies
• A present day update on the Whitehead family, including news about their new book “Praying For Emily”